LOX and pulmonary fibrosis: To this end, we demonstrated that YAP inhibition, using either a pharmacological compound (VP) or siRNA-mediated knockdown, reduces LOX expression in AT2 cells in vitro, experimental lung fibrosis in vivo, and human lung fibrosis modeled in PCLS ex vivo.